A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

To join this study, people generally need to be between 50 and 85 years old. Your eye doctor would need to confirm that you have Geographic Atrophy (GA) in at least one eye due to Age-related Macular Degeneration (AMD). The affected area in your eye must be within a specific size range, and your vision in that eye needs to be at a certain level. You also need to be able to comfortably attend all study appointments and undergo required tests, including getting specific vaccinations.

There are several reasons why someone might not be able to participate. For example, if your GA is caused by something other than AMD, or if you also have another serious eye condition like wet AMD, you wouldn't be eligible. You also can't have had certain other eye treatments or surgeries recently, or have other eye conditions that might interfere with how the study is conducted. The researchers will carefully check for all these criteria to make sure the study is right for you.

If you decide to take part in this study, you will be assigned to a treatment group that receives either pozelimab, cemdisiran, a combination of both, or a placebo. The study drugs are given as an injection under the skin, similar to a diabetes shot. You will have regular visits to the clinic where you will undergo various eye exams, including special scans and vision tests, and have blood samples taken. These tests help the researchers track the progression of your GA and monitor for any side effects or how the drugs are working in your body. The exact number and frequency of visits will be explained by the study team. Overall, you'll be part of the study for an extended period, which the research team will detail.